University of California San Francisco

Image
Ajay V. Maker MD, FACS, FSSO
Ajay V.
Maker
MD, FACS, FSSO

Professor of Surgery
Chief, Division of Surgical Oncology
Maurice Galante Distinguished Professor in Surgical Oncology

Address

550 16th Street, #6450
San Francisco, CA 94158
United States

    Biography

    Biography: Dr. Ajay V. Maker M.D. is a surgical oncologist and chief of the UCSF Division of Surgical Oncology. He is an expert in surgically treating complex gastrointestinal and hepatopancreatobiliary diseases (those affecting the liver, pancreas, gallbladder and bile ducts), as well as melanomas and sarcomas. Maker's research aims to improve early detection of pancreas cancer and to develop new therapies for treating metastases (cancers that have spread from a primary site in the body). Under grants awarded by the Department of Defense and National Institutes of Health (NIH), he works on designing novel immunotherapies (treatments that harness the immune system to fight tumors), particularly for liver metastases from colon cancer. He is one of only a few surgeons to receive the NIH MERIT award and U.S. Army Medical Research Acquisition Activity Cancer Impact Award. Maker earned his medical degree at Yale School of Medicine. He completed a residency in general surgery at Brigham and Women's Hospital, an affiliate of Harvard Medical School. He trained in surgical oncology at the NIH and completed postdoctoral studies in tumor immunology at the National Cancer Institute; this research included working in trials that led to the Food and Drug Administration approval of Ipilimumab as a new treatment for metastatic melanoma. He later completed a fellowship in surgical oncology at Memorial Sloan Kettering Cancer Center and then gained experience in minimally invasive surgical techniques at the University of Paris. He came to UCSF from his hometown of Chicago, where he was a tenured professor of surgery and of microbiology and immunology at the University of Illinois at Chicago. In 2015, Maker was the European Society of Surgical Oncology's international traveling fellow and was later honored with the Society of Surgical Oncology's Clinical Investigator Award. He has published more than 170 manuscripts, abstracts and book chapters, and he lectures all over the world. He serves on the editorial boards of many surgical and scientific journals; serves on NIH study sections, which evaluate the merit of proposed research; and has held leadership positions in numerous academic and scientific societies, including program chair of the Americas Hepato-Pancreato-Biliary Association and chair of the Society of Surgical Oncology's gastrointestinal working group. He is also active in various medical societies, including the Surgical Biology Club , Western Surgical Association, American Society of Clinical Oncology and Pancreas Club. He has been named numerous times to Castle Connolly's Top Doctors and Top Doctors for Cancer lists. He is a fellow of the American College of Surgeons and Society of Surgical Oncology. Research Interests and Funding: Dr. Maker graduated from Brown University with honors in fine arts and biology, completing his honors thesis in the NASA-funded lab of Dr. Herman Vandenberg in tissue engineering. Thereafter, he enrolled in the Yale School of Medicine and was selected to enter the Basic Science Research Training Fellowship where he was awarded the ADA Medical Scholars Award and the AAS/Novartis Research Award for his work in the R01-funded lab of surgeon Dana Andersen on elucidating mechanisms of pancreatogenic diabetes. He completed his general surgery residency at Harvard University's Brigham and Women's Hospital and a tumor immunology post-doctorate fellowship in the laboratory of Dr. Steven Rosenberg in the Surgery Branch of the NIH/NCI, during which time he was first author on many of the initial phase I/II trials utilizing anti-CTLA4 antibodies. This work was later honored with the "most cited article" award by the Society of Surgical Oncology. Dr. Maker went on to complete surgical oncology fellowships at the NCI and Memorial Sloan-Kettering Cancer Center, where he continued translational bench research in the Ludwig Cancer Institute, funded, in part, by an ASCO Merit Award and an NCI EDRU U01. He has focused the efforts of his research career on expanding the role of immunotherapy for gastrointestinal tumors and has aligned his clinical practice to coincide with his research interests. His NCI/NIH and DoD-funded research program has identified an immunostimulatory cytokine capable of activating and supporting the proliferation of antigen-specific T-cells to incite an anti-tumor immune response in colorectal liver metastases. This strategy is currently being investigated in combination with oncolytic viruses and immune checkpoint blockade to elicit complete tumor responses. This work has been funded over time as PI by internal funding, the Warren and Clara Cole Foundation of the ACS, the NIH through both K08 and UL1 mechanisms, the DoD (Cancer Impact Award), R37 MERIT from the NCI, and the Society of Surgical Oncology (Investigator of the Year Award). Dr. Maker's lab also investigates novel drug combinations that stimulate immunogenic cell death and that generate anti-tumor immune responses to treat GI tumor liver metastases. As part of these studies, Dr. Maker has developed multiple unique orthotopic animal models in which to study solid organ metastases that have led to multiple federally funded collaborations, including work on the novel Oncopig porcine large animal cancer model for liver and pancreatic cancer. Furthermore, Dr. Maker has been a leader in the international IPMN biomarkers research group, and has developed a gene signature to predict malignancy in IPMN from pancreatic cyst fluid. He houses the international IPMN cyst fluid repository, one of the largest biobanks of its kind, for which he serves as the international PI. With this collaborative, he is currently validating a single-platform biosignature to accurately predict the malignant potential of pancreatic cysts. Finally, as a clinical surgeon with a passion for developing new laparoscopic and robotic techniques in complex surgical oncology, he has also maintained a robust clinical database from which multiple techniques papers and outcomes studies have been generated along with his residents.

    Education

    Institution Degree Dept or School End Date
    Brigham and Women's Hospital/Harvard Medical School General Surgery
    Brown University Bachelor of Arts
    Memorial Sloan-Kettering Cancer Center Surgical Oncology Fellowship
    National Institutes of Health (NIH)/National Cancer Institute (NCI) Post-doctorate Tumor Immunology
    National Institutes of Health (NIH)/National Cancer Institute (NCI), Surgery Branch Surgical Oncology Fellowship
    Yale University School of Medicine M.D.

    Board Certifications

    American Board of Surgery, General Surgery

    Clinical Expertise

    Pancreatic Cysts including Intraductal Mucinous Neoplasms of the Pancreas (IPMN) and Mucinous Cystic Neoplasms (MCN)
    Colorectal Cancer Liver Metastases
    Bile Duct Cancer (Cholangiocarcinoma)
    Choledochal Cysts
    Gallbladder Cancer
    Gastrointestinal Carcinoid Tumor
    Gastrointestinal Stromal Tumor (GIST)
    Liver Cancer (Hepatocellular Carcinoma)
    Liver Cysts
    Liver Metastases
    Melanoma
    Minimally Invasive Robotic and Laparoscopic Liver, Pancreas, & Gastrointestinal Surgery
    Pancreatic Cancer
    Pancreatic Neuroendocrine Tumors
    Soft Tissue Sarcomas
    Stomach (Gastric) Cancer

    Program Affiliations

    Surgical Oncology Clinics, including the Gastrointestinal Oncology Clinic, Liver/pancreas/biliary and soft tissue sarcoma/skin cancer clinics: Mission Bay and Parnassus

    Hepatobiliary and Pancreas Surgery Program

    UCSF Helen Diller Family Comprehensive Cancer Center

    Sarcoma Disease Program

    Melanoma/Skin Cancer Disease Program

    Grants and Funding

    • Stimulating Lymphocyte Activation Combined with Inhibition of Immunosuppressive Signals in Colon Cancer Metastases | NIH | 2020-01-22 - 2024-12-31 | Role: Principal Investigator
    • Enhancing anti-tumor immune responses in colon cancer metastases | NIH | 2014-09-17 - 2020-08-31 | Role: Principal Investigator

    Research Narrative

    Dr. Maker graduated from Brown University with honors in fine arts and biology, completing his honors thesis in the NASA-funded lab of Dr. Herman Vandenberg in tissue engineering. Thereafter, he enrolled in the Yale School of Medicine and was selected to enter the Basic Science Research Training Fellowship where he was awarded the ADA Medical Scholars Award and the AAS/Novartis Research Award for his work in the R01-funded lab of surgeon Dana Andersen on elucidating mechanisms of pancreatogenic diabetes. He completed his general surgery residency at Harvard University’s Brigham and Women’s Hospital and a tumor immunology post-doctorate fellowship in the laboratory of Dr. Steven Rosenberg in the Surgery Branch of the NIH/NCI, during which time he was first author on many of the initial phase I/II trials utilizing anti-CTLA4 antibodies. This work was later honored with the “most cited article” award by the Society of Surgical Oncology.

    Dr. Maker went on to complete surgical oncology fellowships at the NCI and Memorial Sloan-Kettering Cancer Center, where he continued translational bench research in the Ludwig Cancer Institute in the labs of Jim Allison and Jed Wolchok, funded, in part, by an ASCO Merit Award and an NCI EDRU U01. He has focused the efforts of his research career on expanding the role of immunotherapy for gastrointestinal tumors and has aligned his clinical practice to coincide with his research interests. His NCI/NIH and DoD-funded research program has identified an immunostimulatory cytokine capable of activating and supporting the proliferation of antigen-specific T-cells to incite an anti-tumor immune response in colorectal liver metastases. This strategy is currently being investigated in combination with oncolytic viruses and immune checkpoint blockade to elicit complete tumor responses. This work has been funded over time as PI by internal funding, the Warren and Clara Cole Foundation of the ACS, the NIH through both K08 and UL1 mechanisms, the DoD (Cancer Impact Award), R37 MERIT from the NCI, and the Society of Surgical Oncology (Investigator of the Year Award).

    Dr. Maker's lab also investigates novel drug combinations that stimulate immunogenic cell death and generate anti-tumor immune responses to treat GI tumor liver metastases. As part of these studies, Dr. Maker has developed multiple unique orthotopic animal models in which to study solid organ metastases that has led to multiple federally funded collaborations, including work on the novel Oncopig porcine large animal cancer model for liver and pancreatic cancer.

    Furthermore, Dr. Maker has been a leader in the international IPMN biomarkers research group, and has developed a gene signature to predict malignancy in IPMN from pancreatic cyst fluid. He houses the international IPMN cyst fluid repository, one of the largest biobanks of its kind, for which he serves as the international PI. With this collaborative, he is currently validating a single-platform
    biosignature to accurately predict the malignant potential of pancreatic cysts.

    Finally, as a clinical surgeon with a passion for developing new laparoscopic and robotic techniques in complex surgical oncology, he has also maintained a robust clinical database from which multiple techniques papers and outcomes studies have been generated along with his residents.

    Research Interests

    Immunotherapies for Cancer

    Novel treatments for liver metastases, including colorectal liver metastases

    Development of novel immunotherapeutics for metastatic GI cancer, including colorectal liver metastases

    Development of biosignatures to guide surgical treatment of pancreatic cancer and pancreatic cysts (IPMN/MCN)

    Publications

    MOST RECENT PUBLICATIONS FROM A TOTAL OF 115
    1. Educating Cancer-Associated Fibroblasts (CAFs): Are They the Student or the Teacher?
      Maker AV, Karakousis G| | View in PubMed
    2. Surgical Cancer Care in Safety-Net Hospitals: a Systematic Review.
      Wong P, Victorino GP, Sadjadi J, Knopf K, Maker AV, Thornblade LW| | View in PubMed
    3. ASO Visual Abstract: A Machine-Learning Approach to Predict Postoperative Pancreatic Fistula after Pancreaticoduodenectomy Using only Preoperatively Known Data.
      Ashraf Ganjouei A, Romero-Hernandez F, Wang JJ, Casey M, Frye W, Hoffman D, Hirose K, Nakakura E, Corvera C, Maker AV, Kirkwood KS, Alseidi A, Adam MA| | View in PubMed
    4. Impact of safety-net hospital burden on achievement of textbook oncologic outcomes following resection in for stage I-IV colorectal cancer.
      Wong P, Victorino GP, Miraflor E, Alseidi A, Maker AV, Thornblade LW| | View in PubMed
    5. A Machine Learning Approach to Predict Postoperative Pancreatic Fistula After Pancreaticoduodenectomy Using Only Preoperatively Known Data.
      Ashraf Ganjouei A, Romero-Hernandez F, Wang JJ, Casey M, Frye W, Hoffman D, Hirose K, Nakakura E, Corvera C, Maker AV, Kirkwood KS, Alseidi A, Adam MA| | View in PubMed
    6. ASO Visual Abstract: National Practice Patterns in Malignant Peritoneal Mesothelioma-Updates in Management and Survival.
      Calthorpe L, Romero-Hernandez F, Casey M, Nunez M, Conroy PC, Hirose K, Kim A, Kirkwood K, Maker AV, Corvera C, Nakakura E, Alseidi A, Adam MA| | View in PubMed
    7. Non-Canonical Activin A Signaling Stimulates Context-Dependent and Cellular-Specific Outcomes in CRC to Promote Tumor Cell Migration and Immune Tolerance.
      Wiley MB, Bauer J, Mehrotra K, Zessner-Spitzenberg J, Kolics Z, Cheng W, Castellanos K, Nash MG, Gui X, Kone L, Maker AV, Qiao G, Reddi D, Church DN, Kerr RS, Kerr DJ, Grippo PJ, Jung B| | View in PubMed
    8. National Practice Patterns in Malignant Peritoneal Mesothelioma: Updates in Management and Survival.
      Calthorpe L, Romero-Hernandez F, Casey M, Nunez M, Conroy PC, Hirose K, Kim A, Kirkwood K, Maker AV, Corvera C, Nakakura E, Alseidi A, Adam MA| | View in PubMed
    9. It is not necessary to resect all mucinous cystic neoplasms of the pancreas: current guidelines do not reflect the actual risk of malignancy.
      Pollini T, Marchegiani G, Facciorusso A, Balduzzi A, Biancotto M, Bassi C, Maker AV, Salvia R| | View in PubMed
    10. Drain Placement After Pancreatic Resection: Friend or Foe For Surgical Site Infections?
      Pollini T, Wong P, Kone LB, Khoury RE, Kabir C, Maker VK, Banulescu M, Maker AV| | View in PubMed
    11. Hypertension Requiring Medication Use: a Silent Predictor of Poor Outcomes After Pancreaticoduodenectomy.
      Lin JJ, Conroy PC, Romero-Hernandez F, Yilma M, Feng J, Hirose K, Nakakura E, Maker AV, Corvera C, Kirkwood K, Alseidi A, Adam MA| | View in PubMed
    12. The Landmark Series: Intraductal Papillary Mucinous Neoplasms of the Pancreas-From Prevalence to Early Cancer Detection.
      Pollini T, Wong P, Maker AV| | View in PubMed
    13. Contemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States.
      Calthorpe L, Romero-Hernandez F, Miller P, Conroy PC, Hirose K, Kim A, Kirkwood K, Nakakura E, Corvera C, Maker AV, Alseidi A, Adam MA| | View in PubMed
    14. Hand-Assisted Versus Pure Minimally-Invasive Distal Pancreatectomy: Is There a Downside to Lending a Hand?
      Miller PN, Romero-Hernandez F, Conroy P, Calthorpe L, Yilma M, Mohamedaly S, Kelly YM, Feng J, Hirose K, Kirkwood K, Maker AV, Corvera C, Nakakura E, Alseidi A, Adam MA| | View in PubMed
    15. Minimally Invasive Distal Pancreatectomy Techniques: A Contemporary Analysis Exploring Trends, Similarities, and Differences to Open Surgery.
      Romero-Hernandez F, Mohamedaly S, Miller P, Rodriguez N, Calthorpe L, Conroy PC, Ganjouei AA, Hirose K, Maker AV, Nakakura E, Corvera C, Kirkwood KS, Alseidi A, Adam MA| | View in PubMed
    16. The tumour immune microenvironment and microbiome of pancreatic intraductal papillary mucinous neoplasms.
      Pollini T, Adsay V, Capurso G, Dal Molin M, Esposito I, Hruban R, Luchini C, Maggino L, Matthaei H, Marchegiani G, Scarpa A, Wood LD, Bassi C, Salvia R, Mino-Kenudson M, Maker AV| | View in PubMed
    17. Diagnostic laparoscopy is underutilized in the staging of gastric adenocarcinoma regardless of hospital type: An US safety net collaborative analysis.
      Leder Macek AJ, Wang A, Turgeon MK, Lee RM, Russell MC, Porembka MR, Alterio R, Ju M, Kronenfeld J, Goel N, Datta J, Maker AV, Fernandez M, Richter H, Berman RS, Correa-Gallego C, Lee AY| | View in PubMed
    18. Physical exam reveals etiology of liver and pancreatic tumors.
      Kone LB, Maker AV| | View in PubMed
    19. Langer's arch: An anatomic variant complicating axillary node dissection.
      Baskin AS, Wang K, Maker AV| | View in PubMed
    20. Robotic Surgery for Biliary Tract Cancer.
      Kone LB, Bystrom PV, Maker AV| | View in PubMed
    21. LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer.
      Qiao G, Kone LB, Phillips EH, Lee SS, Brown GE, Khetani SR, Thakur A, Lum LG, Prabhakar BS, Maker AV| | View in PubMed
    22. Clinical Presentation Patterns and Survival Outcomes of Hispanic Patients With Gastric Cancer.
      Vitiello GA, Hani L, Wang A, Porembka MR, Alterio R, Ju M, Turgeon MK, Lee RM, Russell MC, Kronenfeld J, Goel N, Datta J, Maker AV, Fernandez M, Richter H, Correa-Gallego C, Berman RS, Lee AY| | View in PubMed
    23. Attrition during neoadjuvant chemotherapy for gastric adenocarcinoma is associated with decreased survival: A United States Safety-Net Collaborative analysis.
      Kronenfeld JP, Collier AL, Turgeon MK, Ju M, Alterio R, Wang A, Fernandez M, Porembka MR, Richter H, Lee AY, Russell MC, Merchant NB, Maker AV, Datta J| | View in PubMed
    24. The Evolution of Cancer Immunotherapy.
      Khan M, Maker AV, Jain S| | View in PubMed
    25. Is there a difference in utilization of a perioperative treatment approach for gastric cancer between safety net hospitals and tertiary referral centers?
      Turgeon MK, Lee RM, Keilson JM, Ju MR, Porembka MR, Alterio RE, Kronenfeld J, Datta J, Goel N, Wang A, Lee AY, Fernandez M, Richter H, Maker AV, Maithel SK, Russell MC| | View in PubMed
    26. Race and Gender Differences in Awareness of Colorectal Cancer Screening Tests and Guidelines Among Recently Diagnosed Colon Cancer Patients in an Urban Setting.
      Carnahan LR, Jones L, Brewer KC, Watts EA, Peterson CE, Ferrans CE, Cipriano-Steffens T, Polite B, Maker AV, Chowdhery R, Molina Y, Rauscher GH| | View in PubMed
    27. Combining On-Table Embolization with Immediate Resection to Safely Excise Giant Hepatic Hemangiomas.
      Maker AV, Al Rameni D, Prabhakar N| | View in PubMed
    28. Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo.
      Fernandez MF, Qiao G, Tulla K, Prabhakar BS, Maker AV| | View in PubMed
    29. ASO Author Reflections: How Can We Improve the Postoperative Experience for Our Pancreatic Cancer Patients? A Practical Technique to Optimize Pain Control After Major Abdominal Surgery.
      Maker AV| | View in PubMed
    30. Surgeon-Placed Continuous Wound Infusion Pain Catheters Markedly Decrease Narcotic Use and Improve Outcomes After Pancreatic Tumor Resection.
      Kone LB, Kunda NM, Tran TB, Maker AV| | View in PubMed
    31. Epidural Analgesia Is Associated with Prolonged Length of Stay After Open HPB Surgery in Over 27,000 Patients.
      Kone LB, Maker VK, Banulescu M, Maker AV| | View in PubMed
    32. Perioperative Broad-spectrum Antibiotics are Associated With Decreased Surgical Site Infections Compared to 1st-3rd Generation Cephalosporins After Open Pancreaticoduodenectomy in Patients With Jaundice or a Biliary Stent.
      Kone LB, Torres C, Banulescu M, Maker VK, Maker AV| | View in PubMed
    33. Should Drains Suck? A Propensity Score Analysis of Closed-Suction Versus Closed-Gravity Drainage After Pancreatectomy.
      Kone LB, Maker VK, Banulescu M, Maker AV| | View in PubMed
    34. Oncolytic adenovirus encoding LIGHT (TNFSF14) inhibits tumor growth via activating anti-tumor immune responses in 4T1 mouse mammary tumor model in immune competent syngeneic mice.
      Dai S, Lv Y, Xu W, Yang Y, Liu C, Dong X, Zhang H, Prabhakar BS, Maker AV, Seth P, Wang H| | View in PubMed
    35. Management of Cancer Surgery Cases During the COVID-19 Pandemic: Considerations.
      Bartlett DL, Howe JR, Chang G, Crago A, Hogg M, Karakousis G, Levine E, Maker A, Mamounas E, McGuire K, Merchant N, Shibata D, Sohn V, Solorzano C, Turaga K, White R, Yang A, Yoon S, Society of Surgical Oncology| | View in PubMed
    36. A propensity score analysis of over 12,000 pancreaticojejunal anastomoses after pancreaticoduodenectomy: does technique impact the clinically relevant fistula rate?
      Kone LB, Maker VK, Banulescu M, Maker AV| | View in PubMed
    37. MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer.
      Saini S, Sripada L, Tulla K, Qiao G, Kunda N, Maker AV, Prabhakar BS| | View in PubMed
    38. Cyst Fluid Biosignature to Predict Intraductal Papillary Mucinous Neoplasms of the Pancreas with High Malignant Potential.
      Maker AV, Hu V, Kadkol SS, Hong L, Brugge W, Winter J, Yeo CJ, Hackert T, Büchler M, Lawlor RT, Salvia R, Scarpa A, Bassi C, Green S| | View in PubMed
    39. Loss of MADD expression inhibits cellular growth and metastasis in anaplastic thyroid cancer.
      Saini S, Sripada L, Tulla K, Kumar P, Yue F, Kunda N, Maker AV, Prabhakar BS| | View in PubMed
    40. Impact of Immunotherapy after Resection of Pancreatic Cancer.
      Tran TB, Maker VK, Maker AV| | View in PubMed
    41. Molecular aberrations and signaling cascades implicated in the pathogenesis of anaplastic thyroid cancer.
      Saini S, Maker AV, Burman KD, Prabhakar BS| | View in PubMed
    42. Management of asymptomatic, well-differentiated PNETs: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association.
      Mansour JC, Chavin K, Morris-Stiff G, Warner SG, Cardona K, Fong ZV, Maker A, Libutti SK, Warren R, St Hill C, Celinski S, Newell P, Ly QP, Howe J, Coburn N| | View in PubMed
    43. Does attending a Delphi consensus conference impact surgeon attitudes? Survey results from the Americas HepatoPancreatoBiliary Association consensus conference on small asymptomatic pancreatic neuroendocrine tumors.
      Maker AV, Tran TB, Coburn N, Fong ZV, Cardona K, Newell P, Morris-Stiff G, Chavin K, Mansour J, members of the AHPBA Research Committee Consensus Conference| | View in PubMed
    44. Therapeutic advances in anaplastic thyroid cancer: a current perspective.
      Saini S, Tulla K, Maker AV, Burman KD, Prabhakar BS| | View in PubMed
    45. ASO Author Reflections: Improving Identification of Intraductal Papillary Mucinous Neoplasm Patients at Risk-Current Status and the Role of IPMN Molecular Biomarkers.
      Maker AV| | View in PubMed
    46. Identification of a Novel OX40L+ Dendritic Cell Subset That Selectively Expands Regulatory T cells.
      Marinelarena A, Bhattacharya P, Kumar P, Maker AV, Prabhakar BS| | View in PubMed
    47. KRASG12D and TP53R167H Cooperate to Induce Pancreatic Ductal Adenocarcinoma in Sus scrofa Pigs.
      Principe DR, Overgaard NH, Park AJ, Diaz AM, Torres C, McKinney R, Dorman MJ, Castellanos K, Schwind R, Dawson DW, Rana A, Maker A, Munshi HG, Rund LA, Grippo PJ, Schook LB| | View in PubMed
    48. Vaccination With Mitoxantrone-Treated Primary Colon Cancer Cells Enhances Tumor-Infiltrating Lymphocytes and Clinical Responses in Colorectal Liver Metastases.
      Qin J, Kunda NM, Qiao G, Tulla K, Prabhakar BS, Maker AV| | View in PubMed
    49. Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation.
      Kumar P, Marinelarena A, Raghunathan D, Ragothaman VK, Saini S, Bhattacharya P, Fan J, Epstein AL, Maker AV, Prabhakar BS| | View in PubMed
    50. What is the Incidence of Malignancy in Resected Intraductal Papillary Mucinous Neoplasms? An Analysis of Over 100 US Institutions in a Single Year.
      Khoury RE, Kabir C, Maker VK, Banulescu M, Wasserman M, Maker AV| | View in PubMed
    51. Do Drains Contribute to Pancreatic Fistulae? Analysis of over 5000 Pancreatectomy Patients.
      El Khoury R, Kabir C, Maker VK, Banulescu M, Wasserman M, Maker AV| | View in PubMed
    52. Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.
      Tulla KA, Maker AV| | View in PubMed
    53. Port-Site Resection in the Surgical Management of Incidental Gallbladder Cancer: A Still Inconclusive Question: A Reply.
      Maker AV, Jarnagin WR| | View in PubMed
    54. Examining racial disparities in colon cancer clinical delay in the Colon Cancer Patterns of Care in Chicago study.
      Jones LA, Ferrans CE, Polite BN, Brewer KC, Maker AV, Pauls HA, Rauscher GH| | View in PubMed
    55. The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform.
      Schachtschneider KM, Schwind RM, Newson J, Kinachtchouk N, Rizko M, Mendoza-Elias N, Grippo P, Principe DR, Park A, Overgaard NH, Jungersen G, Garcia KD, Maker AV, Rund LA, Ozer H, Gaba RC, Schook LB| | View in PubMed
    56. PKC-ѳ is dispensable for OX40L-induced TCR-independent Treg proliferation but contributes by enabling IL-2 production from effector T-cells.
      Alharshawi K, Marinelarena A, Kumar P, El-Sayed O, Bhattacharya P, Sun Z, Epstein AL, Maker AV, Prabhakar BS| | View in PubMed
    57. Perioperative management of endocrine insufficiency after total pancreatectomy for neoplasia.
      Maker AV, Sheikh R, Bhagia V, Diabetes Control and Complications Trial (DCCT) Research Group| | View in PubMed
    58. A Technique to Define Extrahepatic Biliary Anatomy Using Robotic Near-Infrared Fluorescent Cholangiography.
      Maker AV, Kunda N| | View in PubMed
    59. Targeting cancer with tumor-specific therapeutic strategies-metabolic reprogramming beyond the Warburg effect.
      Grippo P, Maker AV| | View in PubMed
    60. Mitochondrial protein 18 (MTP18) plays a pro-apoptotic role in chemotherapy-induced gastric cancer cell apoptosis.
      Aung LHH, Li R, Prabhakar BS, Maker AV, Li P| | View in PubMed
    61. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
      Ejaz A, Casadaban L, Maker AV| | View in PubMed
    62. LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases.
      Qiao G, Qin J, Kunda N, Calata JF, Mahmud DL, Gann P, Fu YX, Rosenberg SA, Prabhakar BS, Maker AV| | View in PubMed
    63. Isolated Pancreatic Uncinate Duct IPMN.
      Maker AV, Maker VK| | View in PubMed
    64. Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death.
      Qin J, Kunda N, Qiao G, Calata JF, Pardiwala K, Prabhakar BS, Maker AV| | View in PubMed
    65. Can Colon Cancer Recurrence and Metastases Be Determined After Surgical Resection Using a Gene Expression Signature?
      Casadaban L, Maker AV| | View in PubMed
    66. Gene-expression profiling to predict responsiveness to immunotherapy.
      Jamieson NB, Maker AV| | View in PubMed
    67. Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis.
      Carr RM, Qiao G, Qin J, Jayaraman S, Prabhakar BS, Maker AV| | View in PubMed
    68. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer.
      Casadaban L, Rauscher G, Aklilu M, Villenes D, Freels S, Maker AV| | View in PubMed
    69. Techniques to perform robotic left adrenalectomy in the obese patient.
      Maker AV, Maker VK| | View in PubMed
    70. Hepatectomy After Yttrium-90 (Y90) Radioembolization-Induced Liver Fibrosis.
      Maker AV, August C, Maker VK, Weisenberg E| | View in PubMed
    71. A Minimally Invasive Technique to Obtain Optimal Tumor Margins in Anatomically Confined Locations Using a Contoured Stapler.
      Maker AV, Valbuena V, Maker VK| | View in PubMed
    72. Precise identification of immunotherapeutic targets for solid malignancies using clues within the tumor microenvironment-Evidence to turn on the LIGHT.
      Maker AV| | View in PubMed
    73. The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses.
      Maker AV, Prabhakar B, Pardiwala K| | View in PubMed
    74. Techniques to perform a laparoscopic right adrenalectomy for metastases abutting the liver, renal vein, and posterior vena cava.
      Maker AV, Carr R| | View in PubMed
    75. Symptomatic Massive Splenomegaly in Persistent Polyclonal B-cell Lymphocytosis Requiring Splenectomy.
      Bhagwandin SB, Weisenberg ES, Ozer H, Maker AV| | View in PubMed
    76. Tailoring GIST therapy—biology is still king.
      Maker AV| | View in PubMed
    77. Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features.
      Kopanja D, Pandey A, Kiefer M, Wang Z, Chandan N, Carr JR, Franks R, Yu DY, Guzman G, Maker A, Raychaudhuri P| | View in PubMed
    78. Simultaneous Occurrence of Glandular and Neuroendocrine Components in Lymph Node Metastasis of Gastric MANEC.
      August C, Maker AV, Weisenberg E| | View in PubMed
    79. Closure of Melanoma Defects on the Sole of the Foot Using Glaborous Skin: The End of the Flap?
      Maker AV, Iteld L| | View in PubMed
    80. Operative management of portal annular pancreas during pancreaticoduodenectomy.
      Pardiwala KH, Maker AV| | View in PubMed
    81. Genetic evidence that intratumoral T-cell proliferation and activation are associated with recurrence and survival in patients with resected colorectal liver metastases.
      Maker AV, Ito H, Mo Q, Weisenberg E, Qin LX, Turcotte S, Maithel S, Shia J, Blumgart L, Fong Y, Jarnagin WR, DeMatteo RP, D'Angelica MI| | View in PubMed
    82. Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms.
      Maker AV, Carrara S, Jamieson NB, Pelaez-Luna M, Lennon AM, Dal Molin M, Scarpa A, Frulloni L, Brugge WR| | View in PubMed
    83. Appendicitis secondary to metastatic melanoma: review of the National Institutes of Health experience.
      Kitano M, Maker AV, Lanier BJ, Danforth DN, Kammula US| | View in PubMed
    84. Calcifying fibrous tumor of the small intestine associated with Castleman-like lymphadenopathy.
      Valladolid G, Weisenberg E, Sundaresan R, Maker AV| | View in PubMed
    85. Dedifferentiated gastrointestinal stromal tumor arising de novo from the small intestine.
      Choi JJ, Sinada-Bottros L, Maker AV, Weisenberg E| | View in PubMed
    86. IG20/MADD plays a critical role in glucose-induced insulin secretion.
      Li LC, Wang Y, Carr R, Haddad CS, Li Z, Qian L, Oberholzer J, Maker AV, Wang Q, Prabhakar BS| | View in PubMed
    87. Gene expression profiles accurately predict outcome following liver resection in patients with metastatic colorectal cancer.
      Ito H, Mo Q, Qin LX, Viale A, Maithel SK, Maker AV, Shia J, Kingham P, Allen P, DeMatteo RP, Fong Y, Jarnagin WR, D'Angelica M| | View in PubMed
    88. Benign adrenal hemangiomas may mimic metastases on PET.
      Calata JF, Sukerkar AN, August CZ, Maker AV| | View in PubMed
    89. Management of patients with abdominal malignancy after remote jejunoileal bypass: surgical considerations decades later.
      Kaminski JP, Maker VK, Maker AV| | View in PubMed
    90. A technique for laparoendoscopic resection of posterior fundic gastric GISTs without need for a gastrotomy.
      Maker AV| | View in PubMed
    91. Survival after resection of cutaneous adnexal carcinomas with eccrine differentiation: risk factors and trends in outcomes.
      Avraham JB, Villines D, Maker VK, August C, Maker AV| | View in PubMed
    92. Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases.
      Qin JZ, Upadhyay V, Prabhakar B, Maker AV| | View in PubMed
    93. MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.
      Turner A, Li LC, Pilli T, Qian L, Wiley EL, Setty S, Christov K, Ganesh L, Maker AV, Li P, Kanteti P, Das Gupta TK, Prabhakar BS| | View in PubMed
    94. Primary hepatic lymphoma presenting as an isolated solitary hepatic cyst.
      Valladolid G, Adams LL, Weisenberg E, Maker VK, Maker AV| | View in PubMed
    95. Can we predict which residents are going to pass/fail the oral boards?
      Maker VK, Zahedi MM, Villines D, Maker AV| | View in PubMed
    96. Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases.
      Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC, Hedvat CV, Gonen M, Jarnagin WR, Fong Y, D'Angelica MI, DeMatteo RP| | View in PubMed
    97. Malignant masquerade of xanthogranulomatous cholecystitis on intraoperative ultrasound of the liver.
      Maker AV, Maker VK| | View in PubMed
    98. Video: totally laparoscopic left lateral segmentectomy for hepatic malignancies: a modified technique.
      Maker AV, Jamal W, Gayet B| | View in PubMed
    99. Is port site resection necessary in the surgical management of gallbladder cancer?
      Maker AV, Butte JM, Oxenberg J, Kuk D, Gonen M, Fong Y, Dematteo RP, D'Angelica MI, Allen PJ, Jarnagin WR| | View in PubMed
    100. Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells.
      Li LC, Jayaram S, Ganesh L, Qian L, Rotmensch J, Maker AV, Prabhakar BS| | View in PubMed
    101. Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas.
      Maker AV, Katabi N, Qin LX, Klimstra DS, Schattner M, Brennan MF, Jarnagin WR, Allen PJ| | View in PubMed
    102. Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas.
      Maker AV, Katabi N, Gonen M, DeMatteo RP, D'Angelica MI, Fong Y, Jarnagin WR, Brennan MF, Allen PJ| | View in PubMed
    103. Randomized clinical trials in pancreatic adenocarcinoma.
      Rudloff U, Maker AV, Brennan MF, Allen PJ| | View in PubMed
    104. Novel presentation of a familial pancreatic cancer syndrome.
      Maker AV, Warth JA, Zinner MJ| | View in PubMed
    105. Cytology from pancreatic cysts has marginal utility in surgical decision-making.
      Maker AV, Lee LS, Raut CP, Clancy TE, Swanson RS| | View in PubMed
    106. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma.
      Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, Allen T, Mavroukakis SA, Attia P, Rosenberg SA| | View in PubMed
    107. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.
      Attia P, Powell DJ, Maker AV, Kreitman RJ, Pastan I, Rosenberg SA| | View in PubMed
    108. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.
      Maker AV, Attia P, Rosenberg SA| | View in PubMed
    109. Images in cardiothoracic surgery. Active malignant pleural effusion captured through the thoracoscope.
      Maker AV, Nguyen DM| | View in PubMed
    110. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
      Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA| | View in PubMed
    111. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
      Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA| | View in PubMed
    112. Loss of S100 antigenicity in metastatic melanoma.
      Aisner DL, Maker A, Rosenberg SA, Berman DM| | View in PubMed
    113. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
      Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA| | View in PubMed
    114. Rapid acute amiodarone-induced hepatotoxicity in a burn patient.
      Maker AV, Orgill DP| | View in PubMed
    115. Insulin receptor (IR) and glucose transporter 2 (GLUT2) proteins form a complex on the rat hepatocyte membrane.
      Eisenberg ML, Maker AV, Slezak LA, Nathan JD, Sritharan KC, Jena BP, Geibel JP, Andersen DK| | View in PubMed